10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Silence Therapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was -341.24%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Silence Therapeutics's 10-Year ROIIC % or its related term are showing as below:
SLN's 10-Year ROIIC % is ranked worse than 83.32% of 1103
companies
in the Biotechnology industry
Industry Median: -19.8
vs SLN: -341.24
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Silence Therapeutics 10-Year ROIIC % Related Terms
Silence Therapeutics 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLN vs IMRX, VRXA, MGNX: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Silence Therapeutics's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's 10-Year ROIIC % falls into.
Silence Therapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -89.753 (Dec. 2025) - -10.1991231 (Dec. 2015) )
/
( 35.936 (Dec. 2025) - 12.623 (Dec. 2015) )
=
-79.5538769
/
23.313
=
-341.24%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Silence Therapeutics (SLN) has a 10-Year ROIIC % of -341.24 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #919 out of 1103 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Silence Therapeutics' 10-Year ROIIC % too high?
Silence Therapeutics' current 10-Year ROIIC % is -341.24. Based on the distribution chart, Silence Therapeutics ranks #919 out of 1103 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' 10-Year ROIIC % compare to IMRX and VRXA?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #919 out of 1103 companies for 10-Year ROIIC %. This places Silence Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current 10-Year ROIIC % is -341.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.34, compared to a current price of $9.95 — trading 2826.5% above its estimated fair value. The current 10-Year ROIIC % is -341.24. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current 10-Year ROIIC % is -341.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $9.95 is trading 2826.5% above its estimated GF Value™ of $0.34.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
10-Year ROIIC %: -341.24
GF Value™: $0.34 vs. price of $9.95 (2826.5% above fair value)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score
Get the complete analysis for SLN
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
